Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state

References

• Harvey PD, Bowie CR. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother 2005;6:337–46
   PubMed Web of Science ®Google Scholar
• DiNunzio JC, Williams RO III. CNS disorders-current treatment options and the prospects for advanced therapies. Drug Dev Ind Pharm 2008;34:1141–67
   PubMed Web of Science ®Google Scholar
• Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev 2007;13:137–77
   PubMedGoogle Scholar
• Hamelin BA, Allard S, Laplante L, et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 1998;18:9–15
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, et al. Single-and multiple-dose pharmacokinetics of ziprasidone under nonfasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49:5S–13S
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Canas F, Gallhofer B, et al. Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opin Pharmacother 2010;11:2199–220
   PubMed Web of Science ®Google Scholar
• Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. J Adv Ther 2009;26:739–48
   PubMed Web of Science ®Google Scholar
• McCreadie R, Macdonald E, Blacklock C, et al. Dietary intake of schizophrenic patient in Nithsdale, Scotland: case-control study. BMJ 1988;317:784–5
   Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatr 2002;63:1121–8
   PubMed Web of Science ®Google Scholar
• Thombrea AG, Shah JC, Sagawa K, et al. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int J Pharm 2012;428:8–17
   PubMed Web of Science ®Google Scholar
• Thombre AG, Herbig SM, Alderman JA. Improved ziprasidone formulations with enhanced bioavailability in the fasted state and a reduced food effect. Pharm Res 2011;28:3159–70
   PubMed Web of Science ®Google Scholar
• Preskom SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 2005;44:1117–33
   PubMed Web of Science ®Google Scholar
• Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977;66:1–19
   PubMed Web of Science ®Google Scholar
• Rautio J, Kumpulainen H, Heimbach T, et al. Savolainen, prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255–70
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004;3:785–96
   PubMed Web of Science ®Google Scholar
• Nie S, Zhang S, Pan W, et al. In vitro and in vivo studies on the complexes of glipizide with water-soluble β-cyclodextrin-epichlorohydrin polymers. Drug Dev Ind Pharm 2011;37:606–12
   PubMed Web of Science ®Google Scholar
• Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)-block-poly (l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev 2002;54:169–90
   PubMed Web of Science ®Google Scholar
• Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301–4
   PubMed Web of Science ®Google Scholar
• Fatouros DG, Deen GR, Arleth L, et al. Structural development of self-nano emulsifying drug delivery systems (SNEDDS) during in vitro lipid digestion monitored by small-angle X-ray scattering. Pharm Res 2007;24:1844–53
   PubMed Web of Science ®Google Scholar
• Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm 1998;160:229–37
   Web of Science ®Google Scholar
• Potta SG, Minemi S, Nukala RK, et al. Development of solid lipid nanoparticles for enhanced solubility of poorly soluble drugs. J Biomed Nanotechnol 2010;6:634–40
   PubMed Web of Science ®Google Scholar
• Li X, Jiang C, Pan L, et al. Effects of preparing techniques and aging on dissolution behavior of the solid dispersions of NF/Soluplus/Kollidon SR: identification and classification by a combined analysis by FT-IR spectroscopy and computational approaches. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.938080
   Web of Science ®Google Scholar
• Collett JH, Popli H. Poloxamer. In: Kibbe AH, ed. Handbook of pharmaceutical excipients. 3rd ed. London: Pharmaceutical Press; 2000:385–8
   Google Scholar
• Newa M, Bhandari KH, Li DX, et al. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007;343:228–37
   PubMed Web of Science ®Google Scholar
• Umesh M, Naveen S, Amit C, Bhatt DC. Physical properties and dissolution behaviour of meloxicam/poloxamer solid dispersions prepared by hot melt method and microwave assisted method. IJRPS (Jaipur, India) 2012;2:64–74
   Google Scholar
• Prasanna TV, Rani BN, Rao AS, et al. Design and evaluation of solid dispersed tadalafil tablets. IJPSR 2012;3:4738–44
   Google Scholar
• Li H, Yin X, Ji J, et al. Micro-structural investigation to the controlled release kinetics of monolith osmoticpump tablets via synchrotron radiation X-ray microtomography. Int J Pharm 2012;427:270–5
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Dong HY, Peng B, et al. Design of an expert system for the development and formulation of push-pullosmotic pump tablets containing poorly water-soluble drugs. Int J Pharm 2011;410:41–7
   PubMed Web of Science ®Google Scholar
• Malaterre V, Ogorka J, Loggia N, et al. Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm 2009;73:311–23
   PubMed Web of Science ®Google Scholar
• Herrlich S, Spieth S, Messner S, et al. Osmotic micropumps for drug delivery. Adv Drug Deliv Rev 2012;64:1617–27
   PubMed Web of Science ®Google Scholar
• Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987–91
   PubMed Web of Science ®Google Scholar
• Shokri J, Ahmadi P, Rashidi P, et al. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm 2008;68:289–97
   PubMed Web of Science ®Google Scholar
• Zhang X, Yi Y, Qi J, et al. Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs. Int J Pharm 2013;452:233–40
   PubMed Web of Science ®Google Scholar
• Xu H, Li Z, Pan H, et al. A novel bi-layer ascending release osmotic pump tablet: in vitro investigation and in vivo investigation in pharmacokinetic study and IVIVC evaluation. Int J Pharm 2013;458:181–7
   PubMed Web of Science ®Google Scholar
• Xie Y, Lu Y, Qi J, et al. Synchronized and controlled release of multiple components in silymarin achieved by the osmotic release strategy. Int J Pharm 2013;441:111–20
   PubMed Web of Science ®Google Scholar